1 / 3

Japan API Market Trends, Size, Competitive Analysis and Forecast - 2019-2025

The Japan API market is estimated to witness a growth rate of around 7.0% during the forecast period.

nabeelomr
Download Presentation

Japan API Market Trends, Size, Competitive Analysis and Forecast - 2019-2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Japan API market is estimated to witness a growth rate of around 7.0% during the forecast period. Robust healthcare expenditure on R&D of pharmaceutical drugs and presence of API manufacturers are augmenting the country’s market growth. Moreover, the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases (CVDs) are resulting in a significant market for drug manufacturers in Japan for the treatment of such diseases. In 2018, as per World Health Organization, there were around 883 thousand cases of cancer that were registered in which 148,000 cases were of colon cancer followed by 119,000 cases of lung cancer and 115,000 cases of stomach cancer. Breast cancer and prostate cancer cases have shown rise as well. The other major cancers in Japan are prostrate, breast, liver, and pancreas among others. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/japan-api-market The Japan API market is segmented on the basis of type, type of synthesis, manufacturer type, therapeutics, and region. On the basis of type, the market is divided into a generic API and branded API. The branded API segment is estimated to be the dominant segment over the forecast period. On the basis of the type of synthesis, the market is classified into biotech API, synthetic API, and others. The synthetic API segment held the dominant position in the Japan API market in 2018. Furthermore, the market is classified on the basis of therapeutics into cardiovascular drugs, oncology drugs, neurology drugs, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and others. Browse for Full Report at: https://www.omrglobal.com/industry-reports/japan-api-market 5. Market Segmentation 5.1. Japan API Market by Type 5.1.1. General API 5.1.2. Branded API 5.2. Japan API Market by Type of Synthesis

  2. 5.2.1. Biotech API 5.2.2. Synthetic API 5.2.3. Others (High Potency API) 5.3. Japan API Market by Therapeutics 5.3.1. Cardiovascular Drugs 5.3.2. Oncology Drugs 5.3.3. Neurology Drugs 5.3.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 5.3.5. Others (Orthopedic Drugs) 6. Company Profiles 6.1. AbbVie Inc. 6.2. Aesica Pharmaceuticals, Ltd. 6.3. Almac group PLC 6.4. Aurobindo Pharma 6.5. Boehringer Ingelheim International GmbH 6.6. Cipla Ltd. 6.7. Dr. Reddy’s Laboratories Ltd. 6.8. GlaxoSmithKline PLC 6.9. Novartis International AG 6.10. Piramal Enterprises Ltd. 6.11. Sanofi SA 6.12. Siegfried Holding AG 6.13. Sun Pharmaceutical Industries Ltd.

  3. 6.14. Teva Pharmaceutical Industries Ltd. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/japan-api-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

More Related